GlassScriptPhysician profile
Stephanie Yurochko Clop
NPI 1063494771
$16,272.00
in general payments reported to CMS, 2019-2025
65 companies · $3,974 in 2025
The $3,974 reported for 2025 was more than what 96% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $499 · 2021: $2,283 · 2022: $1,906 · 2023: $2,780 · 2024: $4,512 · 2025: $3,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,265.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,824.70 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Medtronic, INC. | $1,201.98 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Lundbeck LLC | $1,114.93 | 2020-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $1,007.11 | 2023-2025 | Mavenclad |
| Lilly USA, LLC | $983.62 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Abbott Laboratories | $696.81 | 2020-2023 | Infinity |
| Pfizer INC. | $614.28 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $409.90 | 2020-2025 | Belbuca, Xtampza |
| Biogen, INC. | $352.26 | 2023-2025 | Tysabri, Leqembi |
| Averitas Pharma INC. | $327.32 | 2023-2024 | Qutenza |
| Grt US Holding, INC. | $299.95 | 2021-2022 | |
| Axsome Therapeutics, INC. | $291.35 | 2023-2025 | Sunosi, Symbravo |
| Eisai INC. | $286.61 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $277.83 | 2021-2025 | Xeomin, Ampyra, Inbrija |
| Arbor Pharmaceuticals, INC. | $275.90 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Clop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.